Provided by Tiger Trade Technology Pte. Ltd.

Cognition Therapeutics, Inc

1.01
-0.0200-1.94%
Volume:271.77K
Turnover:271.78K
Market Cap:96.04M
PE:-5.22
High:1.03
Open:1.02
Low:0.9815
Close:1.03
52wk High:2.67
52wk Low:0.5501
Shares:95.09M
Float Shares:85.42M
Volume Ratio:1.25
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1936
EPS(LYR):-0.3228
ROE:-83.76%
ROA:-78.18%
PB:2.91
PE(LYR):-3.13

Loading ...

Cognition Therapeutics CMO Anthony Caggiano acquires $11,100 common shares

Reuters
·
Apr 21

Cognition Therapeutics CEO presents at Needham Virtual Healthcare Conference, updates Alzheimer’s, DLB programs

Reuters
·
Apr 07

Cognition Therapeutics announces availability of CEO shareholder letter

Reuters
·
Apr 01

Cognition Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 28

Cognition Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 27

Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications

TIPRANKS
·
Mar 27

Cognition Therapeutics 2025 net loss narrows as expenses fall

Reuters
·
Mar 26

Cognition Therapeutics Q4 EPS $(0.01) Beats $(0.05) Estimate

Benzinga Earnings
·
Mar 26

Cognition Therapeutics Inc: Meeting With FDA Division of Psychiatry Expected by Mid-2026

THOMSON REUTERS
·
Mar 26

Press Release: Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Dow Jones
·
Mar 26

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

Cognition Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Mar 24

Cognition Therapeutics to report Q4 and full-year 2025 financial results and host conference call

Reuters
·
Mar 23

Cognition Therapeutics reports 86% slowing of NPI-12 decline with zervimesine in Phase 2 DLB study

Reuters
·
Mar 17

Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

GlobeNewswire
·
Mar 17

Cognition Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Mar 16

Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating

TIPRANKS
·
Mar 04

Cognition Therapeutics Advancing Zervimesine (Ct1812) for Dementia With Lewy Bodies (Dlb) Psychosis

THOMSON REUTERS
·
Mar 02

Cognition - to Meet FDA Division of Psychiatry to Discuss a Dlb Psychosis Program by Midyear 2026

THOMSON REUTERS
·
Mar 02

Cognition Therapeutics Plans Registrational Development Program for Zervimesine in DLB Psychosis, Including New Randomized Study and FDA Psychiatry Division Meeting by Mid-2026

Reuters
·
Mar 02